Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Amgen's shares fell late last year after it released phase 2 data for its weight loss candidate, MariTide. Though the stock has rebounded somewhat, it's still down over the past year. MariTide's ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences is a steady dividend payer with a growing payout. For a while, though ...

TERN-601 showed modest weight loss results but falls short compared to competitors like semaglutide and Amgen's MariTide. With a market cap of $383mn and trading at cash, Terns' strategy of ...

That brings us to Amgen. In November, it reported mid-stage clinical trial results for MariTide, an investigational weight loss treatment, and the market responded by sending the stock down more ...

When the company brings its weight loss drug MariTide to market, I bet that people will finally sit up and take notice. In fact, many clued in people have already spotted it hence the recent gains.